Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 3Oligodendroglioma 2Astrocytoma 2Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 3167Cisplatin 3163Carboplatin 2940Paclitaxel 2675Radiotherapy 2648Gemcitabine 2548pembrolizumab 2334Docetaxel 2158Bevacizumab 2129Fluorouracil 1822Capecitabine 1785Oxaliplatin 1713Dexamethasone 1591Nivolumab 1517Doxorubicin 1479Rituximab 1455Etoposide 1342Magnetic Resonance Spectroscopy 1270Irinotecan 1235Leucovorin 1217Cytarabine 1124Pemetrexed 1064Drug Therapy 1062fludarabine 1052Vincristine 958Specimen Handling 940Prednisone 927Cetuximab 921Lenalidomide 917Trastuzumab 903

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × talampanel × Clear all
NCT00267592 2016-05-19

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
72 enrolled
CNS

Glioblastoma

NCT00064363 2012-03-08

Talampanel in Treating Patients With Recurrent High-Grade Glioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00062504 2011-05-23

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
30 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡